Gene or Genome – Page 21

X4 Pharmaceuticals’ Xolremdi Granted Approval for Treating Rare Immunodeficiency Disorder

12 months ago talkbio0Tagged Antagonist muscle action, Approved, CXCR4 gene, United States Food and Drug Administration, WHIM syndrome, Xolremdi

X4 Pharmaceuticals, Xolremdi, approval, rare immunodeficiency disorder, WHIM syndrome, FDA, treatment, breakthrough therapy, CXCR4 antagonist.

Gilead’s Strategic Focus: CymaBay Liver Drug, Trodelvy Data, and Long-Acting PrEP in 2023

12 months ago talkbio0Tagged CymaBay, Gilead, liver drug, PREP gene, readouts, Strategic Focus, Trodelvy

Gilead, CymaBay, liver drug, Trodelvy, readouts, long-acting PrEP, 2023, strategic focus.

CSL Vifor’s Corrective Marketing Initiative to Address Anti-Competitive Concerns

1 year ago talkbio0Tagged anti-competitive practices, competition, Corrective, CSHL1 gene, Drug Industry, fairness, Market, Measures, Vifor

CSL Vifor, marketing campaign, anti-competitive practices, competition law, corrective measures, pharmaceutical industry, competition watchdog, market fairness.

CSL Vifor Proposes Corrective Campaign to Resolve EU Antitrust Probe

1 year ago talkbio0Tagged Antitrust Probe, competition, Corrective Campaign, CSHL1 gene, EU, Multi-Channel Communication, Vifor

CSL Vifor, EU Antitrust Probe, Corrective Campaign, Multi-Channel Communication, Competition

Alecensa: FDA-Approved First ALK Inhibitor for Adjuvant Treatment in Early-Stage ALK-Positive NSCLC

1 year ago talkbio0Tagged Alecensa, ALINA, ALK gene, ALK Positive, Approved, Cessation of life, disease recurrence, Early-stage, genentech, Guidelines, Immunologic Adjuvants, Inhibitor, NCCN, Non-Small Cell Lung Carcinoma, Roche (company), United States Food and Drug Administration

Alecensa, ALK Inhibitor, Adjuvant Treatment, Early-Stage ALK-Positive NSCLC, FDA Approval, Genentech, Roche Group, ALINA Study, 76% Reduction in Disease Recurrence or Death, NCCN Guidelines

Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development

1 year ago1 year ago talkbio0Tagged Biotechnology, BMS, Bristol Myers Squibb, checkpoint inhibitor, Drug Development, GPR65 gene, Immunotherapy for cancer, Investments, Pathios

Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.

Arrowhead’s Plozasiran Projected to Surpass $700M in Sales by 2032, Addressing Major Unmet Needs in Dyslipidemia Treatment

1 year ago talkbio0Tagged 2032, APOC3 gene, Arrowhead, cellular targeting, Dyslipidemias, Familial chylomicronemia syndrome, FCS, Fetal Bovine Serum, GlobalData, Plozasiran, Projections and Predictions, Sales - occupational activity, SHTG, Triglycerides, Unmet Needs

Arrowhead Pharmaceuticals, Plozasiran, Dyslipidemia, GlobalData, Sales Forecast, $700M, 2032, Unmet Needs, Triglyceride Reduction, APOC3 Targeting, SHTG (Severe Hypertriglyceridemia), FCS (Familial Chylomicronemia Syndrome), Mixed Dyslipidemia